Myeloid shifts focus to cancer trials, trims staff

US biotech Myeloid Therapeutics has restructured its operations to concentrate on two cancer programs already in the clinic, a move that has resulted in staff reductions and an uncertain future for its early-stage research work.

Chief executive Daniel Getts confirmed the shift, which affects the company’s preclinical teams, saying Myeloid is prioritizing resources toward clinical development. The restructuring follows continued progress in two Phase I studies: MT-302, which targets TROP2 in solid tumors, and MT-303, aimed at GPC3 in liver cancer.

Mr Getts told Endpoints News that dose escalation is underway in both studies, and Myeloid intends to release detailed monotherapy results once those phases are complete. He added that “the data we are seeing support further investment and positioning in the frontline setting.”